Who are semaglutide combined with metformin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/semaglutide-combined-with-metformin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

semaglutide combined with metformin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

semaglutide combined with metformin (semaglutide combined with metformin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 receptor agonist combined with biguanide. Area: Diabetes.

marketed GLP-1 receptor agonist combined with biguanide GLP-1R; AMPK pathway Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

semaglutide combined with metformin (semaglutide combined with metformin) — The First Affiliated Hospital of Xiamen University. Semaglutide activates GLP-1 receptors to enhance insulin secretion and reduce appetite, while metformin decreases hepatic glucose production and improves insulin sensitivity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
semaglutide combined with metformin TARGET	semaglutide combined with metformin	The First Affiliated Hospital of Xiamen University	marketed	GLP-1 receptor agonist combined with biguanide	GLP-1R; AMPK pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GLP-1 receptor agonist combined with biguanide class)

The First Affiliated Hospital of Xiamen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). semaglutide combined with metformin — Competitive Intelligence Brief. https://druglandscape.com/ci/semaglutide-combined-with-metformin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab